Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
27.45
+0.40 (1.48%)
At close: Apr 28, 2026, 4:00 PM EDT
27.99
+0.54 (1.97%)
After-hours: Apr 28, 2026, 5:51 PM EDT

Neurogene Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
-0.93---
Cost of Revenue
74.8960.8344.3947.5142.26
Gross Profit
-74.89-59.9-44.39-47.51-42.26
Selling, General & Admin
28.3222.6111.199.018.27
Operating Expenses
28.3222.6111.199.018.27
Operating Income
-103.21-82.51-55.58-56.52-50.53
Interest Expense
-0.01-0.01-0.01-0-
Interest & Investment Income
11.558.472.951.340.02
Other Non Operating Income (Expenses)
1.44-0.99-0.03-0.01-
EBT Excluding Unusual Items
-90.23-75.05-52.67-55.19-50.52
Asset Writedown
-0.12-0.09---
Other Unusual Items
--16.36--
Pretax Income
-90.35-75.14-36.32-55.19-50.52
Net Income
-90.35-75.14-36.32-55.19-50.52
Preferred Dividends & Other Adjustments
---49.97--
Net Income to Common
-90.35-75.1413.65-55.19-50.52
Shares Outstanding (Basic)
2118004
Shares Outstanding (Diluted)
2118504
Shares Change (YoY)
21.40%277.22%1080.37%-90.26%-
EPS (Basic)
-4.24-4.2827.76-139.88-12.47
EPS (Diluted)
-4.24-4.282.93-139.88-12.47
Free Cash Flow
-78.36-71.41-51.74-55.05-64.77
Free Cash Flow Per Share
-3.67-4.07-11.11-139.54-15.99
Operating Margin
--8920.43%---
Profit Margin
--8123.68%---
Free Cash Flow Margin
--7720.11%---
EBITDA
-100.12-79.27-52.29-53.32-49.59
D&A For EBITDA
3.093.253.33.20.95
EBIT
-103.21-82.51-55.58-56.52-50.53
Source: S&P Capital IQ. Standard template. Financial Sources.